Evidence map›Paper›PMID 23979174›Full record

ArticleThe pharmacogenomics journal2014

Providing patients with pharmacogenetic test results affects adherence to statin therapy: results of the Additional KIF6 Risk Offers Better Adherence to Statins (AKROBATS) trial.

S L Charland, B C Agatep, V Herrera, B Schrader, F W Frueh, M Ryvkin, J Shabbeer, J J Devlin, H R Superko, E J Stanek

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Personalized rosuvastatin therapy in problem patients with partial statin intolerance.Archives of medical sciences. Atherosclerotic diseases · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Integrating pharmacogenetic testing into primary care.Expert review of precision medicine and drug development · 2017
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

S L Charland1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
B C Agatep1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Avalere Health, LLC, Washington, DC, USA.
V HerreraMedco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA.
B Schrader1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
F W FruehMedco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA.
M Ryvkin1] Medco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA [2] Express Scripts, Franklin Lakes, NJ, USA.
J ShabbeerAriosa Diagnostics, San Jose, CA, USA.
J J DevlinCelera Corporation, Alameda, CA, USA.
H R SuperkoCelera Corporation, Alameda, CA, USA.
E J StanekMedco Research Institute, LLC (currently a wholly owned subsidiary of Express Scripts Holding Co, Inc.), Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the clinical benefit of statin therapy and the numerous strategies used to improve adherence, no strategy has used direct communication of genetic test results to the patient as an adherence and persistence motivator. We investigated in a real-world setting the effect of a process of providing KIF6 test results and risk information directly to 647 tested patients on 6-month statin adherence (proportion of days covered (PDC)) and persistence compared with concurrent non-tested matched controls. Adjusted 6-month statin PDC was significantly greater in tested patients: 0.77 (95% confidence interval (CI) 0.72-0.82) vs controls 0.68 (95% CI 0.63-0.73), P<0.0001. Significantly more tested patients were adherent (PDC⩾0.80) (63.4% (59.6-67.1%) vs 45.0% (41.1-48.8%), P<0.0001) and persisted on therapy (69.1% (65.4-72.5%) vs 53.3% (49.4-57.1%), P<0.0001). Similar results were observed in a secondary comparison with 779 unmatched patients who declined testing. The Additional KIF6 Risk Offers Better Adherence to Statins trial provides the first evidence that pharmacogenetic testing may modify patient adherence.

Indexed as

Patient CompliancePharmacogeneticsAgedFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID23979174

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.